Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1999-11-1
pubmed:abstractText
The mechanism of action of imiquimod 5% cream applied topically to patients with genital warts was evaluated in a double-blind, placebo-controlled study. Imiquimod (16 patients) or placebo (three patients) was applied three times per week for up to 16 weeks. All imiquimod-treated patients had a > or =75% reduction in total wart area while only one of three placebo-treated patients had a similar reduction. Wart biopsies were taken at prestudy, week 6, and end of treatment. Polymerase chain reaction (PCR) for human papillomavirus (HPV) DNA and reverse transcriptase (RT)-PCR for messenger (m)RNAs were used to identify cytokines, cellular markers, viral gene products, and cell cycle markers in these biopsies. Treatment with imiquimod, an immune response modifier, stimulated significant increases in mRNA for interferon (IFN)-alpha, IFN-gamma and 2',5' oligoadenylate synthetase (2',5'-AS) as well as a tendency towards increases in tumor necrosis factor (TNF)-alpha and interleukin-12 p40. Significant increases in mRNA for CD4 and a trend toward increases in CD8 were also observed in imiquimod-treated patients, suggesting activation of a cell mediated immune response. Imiquimod administration was also associated with a significant decrease in viral load as measured by HPV DNA and L1 mRNA. The effects on HPV markers were accompanied by an apparent decrease in mRNA expression for markers of cell proliferation and an increase in mRNA for markers of keratinocyte differentiation and tumor suppressors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0166-3542
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
55-63
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10480263-Adolescent, pubmed-meshheading:10480263-Adult, pubmed-meshheading:10480263-Aminoquinolines, pubmed-meshheading:10480263-Antigens, CD, pubmed-meshheading:10480263-Cell Differentiation, pubmed-meshheading:10480263-Cell Division, pubmed-meshheading:10480263-Condylomata Acuminata, pubmed-meshheading:10480263-Cytokines, pubmed-meshheading:10480263-Double-Blind Method, pubmed-meshheading:10480263-Female, pubmed-meshheading:10480263-Genital Diseases, Female, pubmed-meshheading:10480263-Genital Diseases, Male, pubmed-meshheading:10480263-Humans, pubmed-meshheading:10480263-Interferon Inducers, pubmed-meshheading:10480263-Keratinocytes, pubmed-meshheading:10480263-Male, pubmed-meshheading:10480263-Middle Aged, pubmed-meshheading:10480263-Papillomaviridae, pubmed-meshheading:10480263-Polymerase Chain Reaction, pubmed-meshheading:10480263-RNA, Messenger, pubmed-meshheading:10480263-Viral Load
pubmed:year
1999
pubmed:articleTitle
Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%.
pubmed:affiliation
Department of Microbiology and Immunology, The University of Texas Medical Branch at Galveston, 77555-1019, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial